

CONGRESS OF THE PHILIPPINES }
First Regular Session }

SENATE

S. No. 453

INTRODUCED BY SENATORS MERCADO, PIMENTEL, JR.,
ZIGA, ROMULO AND ANGARA.

AN ACT TO PROMOTE AND ENSURE THE PRODUCTION OF AN ADEQUATE SUPPLY, DISTRIBUTION AND PUBLIC USE AND ACCEPTANCE OF DRUGS AND MEDICINES IDENTIFIED BY THEIR GENERIC NAMES

Be it enacted by the Senate and House of Representatives of the Philippines in Congress assembled:

1 SECTION 1. *Title.*—This Act shall be known as the
2 “Generic Drugs Act of 1988.”

3 SEC. 2. *Statement of Policy.*—It is hereby declared the
4 policy of the State:

5 (1) To promote the use of generic terminology (names)
6 in the importation, manufacture, distribution, marketing
7 and promotion, prescription and dispensing of drugs;

8 (2) To ensure the adequate supply of quality drugs with
9 generic names at the lowest possible cost and endeavor
10 to make them available for free to indigent patients;

031491

1 (3) To encourage the extensive use of drugs with
2 generic names through a rational system of procurement
3 and prescription;

4 (4) To emphasize the scientific basis for the use of
5 drugs, in order that health professionals may become more
6 aware and cognizant of their therapeutic effectiveness;
7 and

8 (5) To promote drug safety by minimizing duplication
9 in medications and/or use of drugs with potentially adverse
10 drug interactions.

11 SEC. 3. *Definition of Terms.*—The following terms are
12 herein defined for purposes of this Act:

13 (1) "Generic name" is the shortened scientific name
14 based on the active ingredient, also known as the Inter-
15 national Non-proprietary Nomenclature (INN), as
16 recommended by the World Health Organization (WHO),
17 in contrast to proprietary name or brand name given by
18 the manufacturers to distinguish their products from com-
19 petitors. The generic name may or may not be the
20 abbreviated form of the chemical name.

21 (2) "Chemical name" is the description of the chemical
22 structure of the drug or medicine and serves as the com-
23 plete identification of a compound.

1 (3) "Drug product" is the finished product form that
2 contains the active ingredient, generally but not neces-
3 sarily in association with the inactive ingredient.

4 (4) "Active ingredient" is the chemical component
5 responsible for the claimed therapeutic effect of the
6 pharmaceutical product.

7 (5) "Drug establishment" is any organization or com-
8 pany involved in the process of manufacturing, import-
9 ation, repacking and/or distribution of drugs or medicines.

10 (6) "Drug outlets" means drugstores, pharmacies, and
11 any other business establishments which sell drugs or
12 medicines.

13 (7) "List of Essential Drugs" is a list of drugs which
14 are needed to diagnose, prevent or cure most of the
15 common diseases or ailments of a vast majority of the
16 population.

17 SEC. 4. *Use of Generic Terminology/Name for Essential*
18 *Drugs.*—The Department of Health shall, within sixty
19 (60) days from the approval of this Act and quarterly
20 or as often thereafter as the Department of Health may
21 deem appropriate and with the assistance of an expert
22 committee which it shall constitute pursuant to the ob-
23 jectives of this Act, draw up a list of essential drugs,
24 using generic terminology/name and in accordance with

1 internationally established criteria as well as, considering
2 prevalent health problems in the country, a list of generic
3 drugs in the manufacture of which the raw materials
4 are derived completely from indigenous sources, and a list
5 of manufacturers of generic drugs duly recognized and
6 certified by the Department of Health as authorized to
7 manufacture and sell generic drugs.

8 The Department of Health shall publish in at least two
9 (2) newspapers of general circulation in the Philippines
10 the aforementioned lists.

11 SEC. 5. *Incentives.*—The use of generic terminology/
12 name in the importation, manufacture, labeling, distribu-
13 tion, prescription, dispensing and sales of drugs in the
14 said lists shall be promoted through such a system of
15 incentives as the Department of Health, the Board of
16 Investments or other government agencies shall jointly
17 promulgate in accordance with incentives provided by
18 existing law.

19 SEC. 6. *Government Health Agencies to Use and Make*
20 *Available Generic Drugs.*—All government physicians and
21 dentists shall purchase, prescribe, dispense, administer
22 and use whenever appropriate, and all pharmacists, nurses,
23 nursing aides, and other persons employed in the field
24 of public health services shall dispense, administer and

1 use generic drugs found in the certified lists referred to
2 in Section 4 hereof, as prescribed by a physician or dentist,
3 in ministering to the needs of patients in public hospitals,
4 clinics, health centers and other health delivery outlets.

5 SEC. 7. *Government Purchases of Drugs with Generic*
6 *Names.*—All purchases of medicines by the Department
7 of Health and/or any other government entity shall be
8 in the form of generic drugs, whenever and wherever
9 available.

10 SEC. 8. *Authority to Import.*—Within three (3) years
11 from the effectivity of this Act, extendible by the President
12 for another two (2) years, and during periods of critical
13 shortages and absolute necessity, the Department of
14 Health is hereby authorized to import raw materials of
15 which there is a shortage for the use of local Filipino
16 manufacturers of drugs to be marketed and sold exclu-
17 sively under generic nomenclature. The President may
18 authorize the importation of raw materials tax and duty-
19 free. The Secretary of Health shall ensure that the
20 imported raw materials are allocated fairly and efficiently
21 among the local Filipino manufacturers. He shall submit
22 to the Office of the President a quarterly report on the
23 quantity, kind and value of the raw materials imported.

24 SEC. 9. *Private Medical and Dental Practitioners.*—
25 Private physicians and dentists, in giving out prescrip-

1 tions, must indicate the generic name of the drug:
2 *Provided*, That for Medicare patients generic drugs shall
3 be prescribed without prejudice to their right to infor-
4 mation about the availability of branded drugs.

5 SEC. 10. *Drug Manufacturers, Importers, Repackers and*
6 *Distributors.*—No manufacturer, importer, repacker, dis-
7 tributor or outlet of brand name drugs included in the
8 lists referred to in Section 4 hereof, shall sell and/or
9 advertise such drugs unless the generic name including
10 indications thereof in bold letters is placed prominently
11 above the brand name.

12 SEC. 11. *Contents of Label of Generic Drugs.*—The label
13 of every generic drug shall contain the following: name
14 and country of origin of the generic drug, name of the
15 manufacturer, date of manufacture and expiration period.

16 SEC. 12. *Drugstores.*—Subject to the rules and regul-
17 ations promulgated by the Secretary of Health, drug-
18 stores shall, within one year from the approval of this
19 Act, include generic drugs in their stock in trade and shall
20 make them regularly available to the public: *Provided*,
21 That drugstores shall post in conspicuous places in their
22 business establishments the lists referred to in Section 4
23 hereof, and which lists shall include the selling prices of
24 such drugs both generic and branded.

1 **SEC. 13. *Required Production.***—Subject to the rules and
2 regulations promulgated by the Secretary of Health,
3 every drug manufacturing company operating in the
4 Philippines shall distribute and make available to the
5 general public the medicine it produces in the form of
6 generic drugs.

7 **SEC. 14. *Education Drive.***—The Department of Health
8 shall conduct a continuous information campaign to make
9 the public aware of generic drugs as an alternative of
10 equal efficacy to the more expensive brand name drugs.
11 Such educational campaign shall include information on
12 the illnesses or symptoms which each generic drug is
13 supposed to cure or alleviate, as well as its contra-
14 indications. The Department of Health shall establish
15 a feedback and evaluation mechanism that shall monitor
16 the progress of the education drive, and shall submit
17 regular reports to Congress.

18 **SEC. 15. *Rules and Regulations.***—The Secretary of
19 Health shall, within six (6) months from the effectivity
20 of this Act, promulgate rules and regulations to implement
21 the objectives of this Act with special emphasis on
22 monitoring strict compliance therewith. The rules and
23 regulations may include the prohibition of use in any
24 drug marketed in the Philippines of ingredients whose

1 use has been banned, withdrawn or restricted in other
2 countries. Rules and regulations with penal sanctions
3 shall take effect fifteen (15) days after completion of its
4 publication in the *Official Gazette* or in two (2) news-
5 papers of general circulation.

6 SEC. 16. *Sanctions*.—Any person who violates any
7 provision of this Act or any regulation issued by the
8 Secretary of Health to carry out the purposes of this
9 Act shall be required to render *pro bono* community service
10 in health or sanitation for a period of not less than thirty
11 (30) days but not more than six (6) months in areas,
12 whether rural or urban, to be designated by the Secretary
13 of Health or by a fine of not less than five thousand pesos
14 (P5,000) but not more than fifteen thousand pesos
15 (P15,000), or both such fine and community service at
16 the discretion of the court. In the first case, the offender
17 shall report to the city or municipal health officer for the
18 purpose of serving his sentence: *Provided*, That the
19 sanction of community service shall apply for the first
20 offense and the sanction of either community service or
21 fine, or both, shall apply for a second or subsequent
22 offense. In case of corporations or juridical persons, the
23 president or the manager thereof shall render the com-
24 munity service required and the fine shall be paid by the

1 corporation or the juridical person: *Provided*, That a
2 failure of the manufacturer, importer, repacker, distri-
3 butor or outlet to comply with the requirements contained
4 in Sections 10, 11 or 13 hereof, will cause the suspension
5 or forfeiture of its license to do business in addition to
6 the sanctions imposed in this section.

7 SEC. 17. *Separability Clause*.—If any provision of this
8 Act is declared invalid, the remainder of this Act or any
9 provision not affected thereby shall remain in force and
10 effect.

11 SEC. 18. *Repealing Clause*.—The provisions of any law,
12 executive order, presidential decree, or other issuances
13 inconsistent with this Act are hereby repealed or modified
14 accordingly.

15 SEC. 19. *Effectivity*.—This Act shall take effect fifteen
16 (15) days after its complete publication in the *Official*
17 *Gazette* or two (2) newspapers of general circulation.

Approved,



○